Market revenue in 2023 | USD 1,856.9 million |
Market revenue in 2030 | USD 4,155.4 million |
Growth rate | 12.2% (CAGR from 2023 to 2030) |
Largest segment | Growth hormone deficiency |
Fastest growing segment | Growth Hormone Deficiency |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Other Applications, Growth Hormone Deficiency |
Key market players worldwide | Novo Nordisk A/S ADR, Eli Lilly and Co, Pfizer Inc, Sandoz Group AG ADR, Roche, Ferring, Ipsen SA, Teva Pharmaceutical Industries Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account